Vitiligo
MONDO:0008661Generalized well circumscribed patches of leukoderma that are generally distributed over symmetric body locations and is due to autoimmune destruction of melanocytes.
137 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
HPV vaccine shows promise for girls on Immune-Suppressing drugs
⭐️ VACCINE ⭐️ CompletedThis study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:36 UTC
-
New booster aims to shield the vulnerable from COVID-19
⭐️ VACCINE ⭐️ CompletedThis study tested an extra dose of the HIPRA COVID-19 vaccine in 241 adults with conditions like HIV, kidney disease, or autoimmune disorders that weaken the immune system. The goal was to see if the booster raises antibody levels against virus variants and remains safe. Research…
Phase: PHASE2, PHASE3 • Sponsor: Hipra Scientific, S.L.U • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 18:38 UTC
-
Lamp vs laser: which light works best for vitiligo?
Disease control CompletedThis study compared two types of ultraviolet light treatments—an excimer lamp and an excimer laser—for repigmenting white patches caused by vitiligo. Adults with at least two matching patches of vitiligo received both treatments on different patches twice a week for 12 weeks. The…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a drug plus light therapy reverse vitiligo? new trial tests the combo
Disease control CompletedThis phase 2 trial tested whether adding the oral drug baricitinib to phototherapy (light treatment) helps restore skin color in adults with progressive vitiligo. 49 participants received either baricitinib plus phototherapy or a placebo plus phototherapy for 36 weeks. The main g…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New ointment shows promise for restoring skin color in vitiligo
Disease control CompletedThis phase 2 trial tested an ointment called MH004 in 156 people with non-segmental vitiligo, a condition that causes white patches on the skin. Participants applied the ointment to affected areas once or twice daily for 24 weeks. The study measured how much skin color returned, …
Phase: PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can a common arthritis drug help stop vitiligo from spreading?
Disease control CompletedThis phase 2 trial tested whether adding methotrexate (a drug used for arthritis) to standard UVB light therapy works better than light therapy alone for adults with active, spreading vitiligo. Thirty-two participants were randomly assigned to receive either methotrexate pills pl…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Molecular map may guide treatment for mysterious inflammatory illnesses
Disease control CompletedThis study tested whether analyzing a patient's DNA and RNA could help doctors pick the right drug for inflammatory diseases that don't fit standard categories. 32 adults with at least two affected organs (including skin) received one of six targeted therapies based on their mole…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody drug shows promise for vitiligo in early trial
Disease control CompletedThis phase 2a trial tested an experimental drug called AMG 714 in 60 adults with vitiligo, a condition that causes white patches on the skin. The drug works by blocking a protein called IL-15, which may play a role in the disease. Participants received either AMG 714 or a placebo…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug VIS171 tested in humans for first time – could it tame autoimmune disease?
Disease control CompletedThis early-phase trial tested a new drug called VIS171 in 61 people: first in healthy volunteers, then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. No results on whether it actually helps the disease are available ye…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a pill plus light therapy restore skin color in vitiligo?
Disease control CompletedThis study tested whether the drug apremilast, taken as a pill twice daily, combined with narrowband UVB light therapy can help restore skin color in people with widespread vitiligo. 80 adults with stable or slowly progressing vitiligo covering at least 10% of their body took par…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a cholesterol drug help stop vitiligo?
Disease control CompletedThis study tested whether adding the cholesterol drug atorvastatin to standard UVB light therapy works better than UVB alone for active vitiligo. 28 adults with active, non-segmental vitiligo took part. The main goal was to see if the combination reduced the amount of skin color …
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cream shows promise for genital vitiligo in early trial
Disease control CompletedThis phase 2 trial tested a cream called ruxolitinib (Opzelura) on 49 people with nonsegmental vitiligo affecting the genitals. Participants applied the cream twice daily for up to 48 weeks to see if it made the white patches less noticeable. The study measured success based on p…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
Can a daily pill bring back skin color? new trial tests ritlecitinib for vitiligo
Disease control CompletedThis Phase 3 study tested ritlecitinib, an oral drug, in 607 adults and adolescents with nonsegmental vitiligo (a type of white patches on the skin). Participants took either the drug or a placebo daily for 52 weeks. The main goals were to see if the drug could improve skin color…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Vitiligo showdown: new drug vs. old combo in Head-to-Head trial
Disease control CompletedThis study tested whether a newer cream (ruxolitinib) works better alone or when combined with two older creams (tacrolimus and corticosteroids) for vitiligo. 120 adults with limited vitiligo (less than 10% of body affected) were split into three groups and treated for 24 weeks. …
Phase: PHASE4 • Sponsor: Dow University of Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Could a common arthritis drug ease skin woes in down syndrome?
Disease control CompletedThis study tested whether tofacitinib, a drug already approved for arthritis, is safe and helpful for immune-related skin conditions in people with Down syndrome. 47 adolescents and adults with Down syndrome and skin issues like eczema or psoriasis took the drug. Researchers chec…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Blue light therapy shows promise for vitiligo repigmentation
Disease control CompletedThis study compared blue light therapy to targeted narrow band UVB for treating stable non-segmental vitiligo in 30 patients. The goal was to see which treatment better restores skin color. Both are light-based therapies, but blue light may be less harsh on the skin.
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 26, 2026 16:55 UTC
-
Blood filter shows promise for autoimmune patients
Disease control CompletedThis study looked at a device called GLOBAFFIN that filters antibodies from the blood to help people with autoimmune diseases. It involved 34 adults and measured how much harmful antibodies were removed and if patients felt better. The goal was to see if the device is safe and wo…
Phase: NA • Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Can early UVB and steroids stop vitiligo in its tracks?
Disease control CompletedThis study tested whether starting treatment early with UVB light therapy and low-dose steroids can stop vitiligo from spreading and improve skin color return. 51 people with different stages of vitiligo were treated for 6 months. Researchers took skin samples to see how immune c…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 26, 2026 12:59 UTC
-
New rapid test for infection and inflammation put to the test
Diagnosis CompletedThis study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New PET tracer aims to light up hidden infections
Diagnosis CompletedThis early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Nano-Silver bandage promises quicker gum recovery after dark spot removal
Symptom relief CompletedThis study tested whether a nano-crystalline silver dressing helps gums heal faster and with less pain after surgical removal of dark gum pigmentation. Twelve adults with moderate to severe gum pigmentation had the surgery, and the silver dressing was compared to a standard dress…
Phase: NA • Sponsor: Damascus University • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Cutting salt and sugar may tame steroid side effects
Symptom relief CompletedThis study looked at whether a diet low in salt and sugar can reduce common side effects of corticosteroid treatment, such as weight gain, high blood pressure, and diabetes. Fifty adults with autoimmune diseases or asthma who were starting high-dose corticosteroids were randomly …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Can an antioxidant boost light therapy for vitiligo?
Symptom relief CompletedThis study tested whether adding a special antioxidant pill (GLISODIN) to standard UVB light therapy helps treat vitiligo better than light therapy alone. Fifty adults with non-segmental vitiligo covering more than 5% of their body took part. The main goal was to see if the combi…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Study explores how family and friends impact caregiver health
Knowledge-focused CompletedThis completed study looked at how the social networks of caregivers affect their stress and health when caring for someone with an inherited disease. Researchers surveyed over 680 participants, including family members and formal caregivers, to understand caregiving burden and s…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists hunt for genetic and environmental triggers of rare muscle diseases
Knowledge-focused CompletedThis study looked at 719 people, including patients with autoimmune connective tissue diseases like myositis, their blood relatives, and healthy volunteers. Researchers collected blood samples and medical histories to find genetic and environmental factors that may trigger these …
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive study reveals COVID-19 risks for autoimmune patients
Knowledge-focused CompletedThis study looked at over 13,000 people with chronic inflammatory rheumatism or autoimmune diseases who had or were suspected to have COVID-19. Researchers tracked how many developed severe COVID-19 requiring intensive care or leading to death. They also examined risk factors lik…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Rituximab infection risk under the microscope
Knowledge-focused CompletedThis completed study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab. The goal was to track how many developed serious infections and to understand what factors increase that risk. Researchers …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Skin biopsy study aims to unlock Vitiligo's repigmentation mystery
Knowledge-focused CompletedThis study compares skin samples from 20 people with vitiligo and 20 healthy volunteers to understand why certain body areas (like the face) repigment well while others (like hands and feet) do not. Researchers will analyze gene activity in skin from five different body sites. Th…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scientists test designer immune molecules in autoimmune diseases
Knowledge-focused CompletedThis study looked at whether specially engineered versions of a natural immune protein (IL-2) can selectively boost regulatory T cells, which help calm the immune system. Researchers took blood samples from 67 people with various autoimmune or inflammatory conditions and tested t…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
AI could cut skin specialist wait times, study hints
Knowledge-focused CompletedThis study tested an artificial intelligence algorithm designed to help primary care doctors decide whether a patient with a skin condition really needs to see a dermatologist. Researchers enrolled 200 adults with skin problems and had their doctors take photos of the affected ar…
Sponsor: AI Labs Group S.L • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Vitiligo linked to higher risk of depression and anxiety in major study
Knowledge-focused CompletedThis study looked at over 36,000 adults in the UK to see if people with vitiligo are more likely to have mental health problems like depression, anxiety, or self-harm compared to those without vitiligo. Researchers used medical records to compare risks and also checked if these r…
Sponsor: Momentum Data • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New drug LAD191 tested for safety in autoimmune patients
Knowledge-focused CompletedThis early-phase study tested the safety and tolerability of a new drug called LAD191 in 69 healthy adults and people with an autoimmune disease. Researchers gave single or multiple doses to see how the body processes the drug and if it causes side effects. The goal was to gather…
Phase: PHASE1 • Sponsor: Almirall, S.A. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Scientists gather clues on mysterious immune defects
Knowledge-focused CompletedThis study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
New study reveals hidden toll of vitiligo on chinese patients
Knowledge-focused CompletedThis study looked at how vitiligo affects people in China, including their treatments and daily life. Researchers observed 100 patients to measure the disease's impact on their skin and quality of life. The goal was to better understand the real-world burden of this condition.
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC